# Adversarial RE-verification verdict — radiation_proctitis (post-fix)

Sidecar: `docs/superpowers/onco-waves/wave9/radiation_proctitis.md`
DeVita grep hits used: lines ~159877–159930 (prostate-RT "Side Effects Post Radiotherapy" — acute urethritis/cystitis/proctitis mgmt, late rectal toxicity, argon-beam coagulation, hyperbaric O2, rectal spacer/ASCENDE-RT/grade≥3 toxicity data ~159600-159860) and ~327179–327190 ("Radiotherapy-Induced Diarrhea" — acute vs. late radiation enteritis/proctitis timing). Also checked sucralfate (~329260-329300, oral-mucositis context only) and formalin (~159912, hemorrhagic-cystitis context only) to confirm those are correctly off-topic for proctitis.

## 1. DOSE LEAK
None. No mg, Gy/cGy, mg/m2, AUC, %, or numbered fraction/session/cycle schedule anywhere in the file. DeVita's own leakable numbers for this topic (HBOT "2.4 atmospheres, median 36 sessions, 90 min/session"; ASCENDE-RT "350%/216% increase" toxicity; "≤1%–2%" severe toxicity; grade≥3 bowel-event percentages by dose arm) all remain correctly omitted/paraphrased qualitatively.

## 2. UNGROUNDED / MISLABELLED CLAIMS
- R1's single required fix — the acute-proctitis "treatment continued through mild-to-moderate symptoms, breaks reserved for severe symptoms" line (now line 12) — is confirmed relabeled: it now ends with "(general oncology standard, not from DeVita's section on this disease)". Re-checked DeVita: no "treatment break" hit is tied to proctitis/pelvic-RT-continuation specifically, so the label is honest and the fix is correctly scoped (label-only, no content change, matches file's existing convention).
- All other previously-labeled items (sucralfate, formalin, iron-deficiency workup, DDx exclusion list, surgical-referral caution, endoscopic-follow-up favoring visual-over-biopsy) remain correctly labeled — re-verified sucralfate/formalin hits in DeVita are oral-mucositis/hemorrhagic-cystitis specific, not proctitis, so the "not from DeVita's section on this disease" tag is accurate.
- Unlabeled (implicitly DeVita-sourced) claims all re-checked as grounded: 6-week acute onset, 2-6-month resolution, symptom list, dietary manipulation + loperamide/diphenoxylate-atropine, sitz baths/hydrocortisone for hemorrhoids, avoid-deep-biopsy/cautery fistula-risk caution, 3-year (rare >5-year) late-toxicity onset, steroid suppositories/sitz baths/fiber for bleeding, argon-beam coagulation, HBOT rationale, rectal spacer/SpaceOAR toxicity reduction, brachytherapy-boost toxicity trade-off (ASCENDE-RT), and "grade 3 or higher" toxicity language (matches DeVita's own "grade ≥3" framing verbatim in the CHHiP/SBRT data) — no drift, no new fabrication introduced by the edit.
- Residual minor observation only, not blocking: "reducing dietary fiber/residue and lactose" is more specific than DeVita's own wording ("dietary manipulations"); this is uncontroversial standard supportive-care detail, not a specific regimen/drug/trial/statistic, so it does not meet the labeling bar under the stated criteria.
- No invented trial names, statistics, or regimens. No claim mis-attributed to DeVita.

## 3. CITATION
Present, correctly formatted: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th ed." Name + edition only, no page numbers.

## 4. VERDICT: CLEAN (ready for R1 re-review)

R1's required relabel is confirmed applied exactly as scoped (no silent content change smuggled in with it). No new or residual fabrication/mislabeling found on re-verification; zero dose leakage.
